继续使用闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为甘李 药业股份有限公司（以下简称"甘李药业"或"公司"）持续督导工作的保荐机 构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上市公司募集 资金监管规则》等有关规定，就甘李药业使用首次公开发行股票闲置募集资金进 行现金管理事项进行了核查，具体情况如下： 一、募集资金基本情况 中信证券股份有限公司 关于甘李药业股份有限公司 （一）投资目的 公司为提高资金的使用效率和收益，在保证募集资金项目投资计划正常实施 的情况下，合理利用部分暂时闲置募集资金购买安全性高、流动性好、满足保本 要求的投资产品（包括协定性存款、结构性存款、定期存款、大额存单、收益凭 证等），实行现金管理为公司和股东谋取较好的投资回报。 （二）资金来源 公司本次委托理财的资金来源系闲置募集资金。 （三）投资额度及期限 公司拟使用不超过 2.5 亿元人民币的暂时闲置募集资金购买安全性高、流动 性好、满足保本要求的投资产品（包括协定性存款、结构性存款、定期存款、大 ...

Core Viewpoint - Gann Li Pharmaceutical Co., Ltd. is set to release 4,256,033 shares of restricted stock for public trading on July 25, 2025, following the expiration of the lock-up period for certain shareholders [1][2][6]. Group 1: Stock Listing Details - The stock listing type is an initial public offering (IPO) with a total of 4,256,033 shares being made available for public trading [1]. - The total number of shares listed for circulation is 4,256,033, which represents 0.71% of the company's total share capital [2][8]. - The company received approval from the China Securities Regulatory Commission for the public offering of 40,200,000 shares, which were listed on June 29, 2020 [1][2]. Group 2: Shareholder Commitments - STRONG LINK INTERNATIONAL LIMITED is the shareholder involved in this restricted stock release, and the shares will be unlocked following a written notice from the controlling shareholder, Gan Zhongru [2][6]. - The lock-up period for the shares was initially set for 12 months post-IPO, with an extension contingent upon the controlling shareholder's notification [2][6]. Group 3: Capital Structure Changes - Following the IPO, the company's total share capital increased from 401,100,000 shares to 561,540,000 shares after a cash dividend distribution and stock issuance [3]. - The current total share capital stands at 601,065,290 shares, with 39,666,689 shares under restricted conditions and 561,398,601 shares freely tradable [8]. Group 4: Regulatory Compliance - The company has complied with all relevant regulations and commitments regarding the release of restricted shares, as confirmed by the sponsoring institution [7]. - The release of the restricted shares aligns with the Shanghai Stock Exchange's listing rules and the commitments made during the IPO process [7].

证券代码：603087 证券简称：甘李药业 公告编号：2025-054 甘李药业股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发股份；股票认购方式为网下，上市股数为4,256,033 股。 一、本次限售股上市类型 经中国证券监督管理委员会《关于核准甘李药业股份有限公司首次公开发行 股票的批复》（证监许可[2020]1075 号）核准，甘李药业股份有限公司（以下简称"甘 李药业"、"公司"）获准向社会公众公开发行人民币普通股（A 股）股票 40,200,000 股，于 2020 年 6 月 29 日在上海证券交易所上市。公司首次公开发行前总股本为 360,900,000 股,首次公开发行后总股本为 401,100,000 股，其中有限售条件流通股 为 360,900,000 股，无限售条件流通股为 40,200,000 股。 本次上市流通的限售股为公司首次公开发行限售股，涉及股东为 STRONG LINK INTERNATIONAL LI ...

中信证券股份有限公司关于甘李药业股份有限公司 首次公开发行部分限售股上市流通的核查意见 公司于 2020 年 7 月 23 日召开 2020 年第二次临时股东大会审议通过《2019 年年度利润分配预案》，公司以利润分配实施前的公司总股本 401,100,000 股为基 数，向全体股东每股派发现金红利 0.5 元（含税），每股派送红股 0.4 股，共计派 发现金红利 200,550,000 元，派送红股 160,440,000 股。上述利润分配方案已实施 完毕，公司总股本由 401,100,000 股增加至 561,540,000 股。 2022 年 11 月 15 日，公司召开 2022 年第一次临时股东大会，审议通过了 《关于<甘李药业股份有限公司 2022 年限制性股票激励计划（草案）>及其摘要 的议案》《关于<甘李药业股份有限公司 2022 年限制性股票激励计划实施考核管 理办法>的议案》及《关于提请股东大会授权董事会办理股权激励相关事宜的议 案》等议案，同意公司采用限制性股票作为激励工具，向激励对象定向发行公司 股票。本次授予的 4,113,200 股限制性股票已于 2022 年 12 月 20 日在 ...

中信证券股份有限公司 关于甘李药业股份有限公司 继续使用闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为甘李 药业股份有限公司（以下简称"甘李药业"或"公司"）持续督导工作的保荐机 构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上市公司募集 资金监管规则》等有关规定，就甘李药业使用首次公开发行股票闲置募集资金进 行现金管理事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准甘李药业股份有限公司首次公开发行 股票的批复》（证监许可[2020]1075 号）核准，公司获准向社会公众公开发行人 民币普通股（A 股）股票 4,020 万股，发行价为每股人民币 63.32 元，共计募集 资金 254,546.40 万元，扣除发行费用后，实际募集资金净额为 244,113.45 万元。 上述募集资金已于 2020 年 6 月 22 日到位，已经安永华明会计师事务所（特殊普 通合伙）验证，并由其出具安永华明（2020）验字第 61234813_A01 ...

关于继续使用闲置募集资金进行现金管理的公告 证券代码：603087 证券简称：甘李药业 公告编号：2025-053 甘李药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、满足保本要求的投资产品（包括协定 性存款、结构性存款、定期存款、大额存单、收益凭证等）。 投资金额：不超过人民币 2.5 亿元，该额度自董事会审议通过之日起不 超过 12 个月，单笔投资产品的期限不超过 12 个月。 履行的审议程序：2025 年 7 月 21 日，甘李药业股份有限公司（以下简 称"公司"）召开的第五届董事会第二次会议及第五届监事会第二次会议审议通过 了《关于继续使用闲置募集资金进行现金管理的议案》。 特别风险提示：公司拟投资安全性高、流动性好、满足保本要求的产品， 但金融市场受宏观经济的影响较大，不排除该项投资受到宏观经济因素影响存在 一定的系统性风险。 公司于 2025 年 7 月 21 日召开的第五届董事会第二次会议，审议通过了《关 于继续使用闲置募集资金进行现金管理的议案》， ...

甘李药业股份有限公司（"公司"）第五届监事会第二次会议于 2025 年 7 月 15 日以电子邮件方式发出会议通知和会议材料，2025 年 7 月 21 日在公司五 层会议室以现场会议的形式召开。本次会议由监事会主席张立主持。应出席监事 3 名，实际出席监事 3 名。本次会议的召开符合《公司法》和《公司章程》的有 关规定，会议决议合法有效。 证券代码：603087 证券简称：甘李药业 公告编号：2025-052 甘李药业股份有限公司 第五届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 公司关于继续使用闲置募集资金进行现金管理的公告》（公告编号：2025-053）。 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： （一）审议通过了《关于继续使用闲置募集资金进行现金管理的议案》 监事会同意公司在保障资金安全及确保不影响募集资金投资项目建设和使 用计划的前提下，继续使用不超过人民币 2.5 亿元的暂时闲置募 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-051 甘李药业股份有限公司 第五届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 甘李药业股份有限公司（"公司"）第五届董事会第二次会议于 2025 年 7 月 15 日以电子邮件方式发出会议通知和会议材料，2025 年 7 月 21 日在公司五 层会议室以现场结合通讯方式召开。本次会议由董事长陈伟先生主持。应出席董 事 9 名，实际出席董事 9 名，公司监事及高级管理人员列席本次会议。本次会议 的召开符合《公司法》和《公司章程》的有关规定，会议决议合法有效。 董事会同意公司在保障资金安全及确保不影响募集资金投资项目建设和使 用计划的前提下，继续使用不超过人民币 2.5 亿元的暂时闲置募集资金适时购买 安全性高、流动性好、满足保本要求的投资产品（包括协定性存款、结构性存款、 定期存款、大额存单、收益凭证等），且该等投资产品不得用于质押，不用于以 证券投资为目的的投资行为。同时不影响募集资金投资计划正常进行。期限自 ...

Core Viewpoint - The Shanghai Health Industry Index has shown significant growth, reflecting the overall performance of major companies in the healthcare, food safety, and environmental sectors listed on the Shanghai Stock Exchange [2]. Group 1: Index Performance - The Shanghai Health Industry Index has increased by 4.93% over the past month, 8.76% over the past three months, and 7.27% year-to-date [2]. - The index is based on the largest 50 listed companies in relevant sectors, using an equal-weighted approach to represent the overall performance of health-related companies [2]. Group 2: Index Composition - The top ten weighted companies in the index include Shanghai Washba (3.12%), WuXi AppTec (2.5%), and others, with the total weight of these companies reflecting their significance in the index [2]. - The index is composed entirely of companies listed on the Shanghai Stock Exchange, with a sector breakdown showing 39.55% in healthcare, 29.68% in consumer goods, 24.70% in industrials, and 6.07% in utilities [2]. Group 3: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [3]. - Each adjustment typically does not exceed 20% of the sample, and weight factors are fixed until the next scheduled adjustment unless special circumstances arise [3].

Summary of Conference Call Notes Industry or Company Involved - The discussion primarily revolves around the pharmaceutical industry, particularly focusing on the implications of U.S. drug pricing policies and U.S.-China trade negotiations on Chinese pharmaceutical companies and their market opportunities. Core Points and Arguments 1. **Positive Impact of U.S.-China Negotiations on Pharmaceuticals** The recent U.S.-China negotiations are viewed as a significant positive for the pharmaceutical sector, alleviating previous concerns regarding trade impacts on drug pricing and exports of innovative drugs and raw materials [1] 2. **U.S. Drug Pricing Policy Changes** Trump's announcement of an executive order to reduce prescription drug prices by 30% to 80% is highlighted. The U.S. drug pricing system, characterized by high list prices, is under scrutiny, with the potential for significant price reductions impacting the market [2][3] 3. **Global Drug Pricing Context** U.S. drug prices are noted to be among the highest globally, particularly for innovative drugs, which are approximately 300% higher than prices in countries like Japan and Germany. This pricing structure encourages innovation but also raises concerns about affordability [3] 4. **Encouragement of Competition** The U.S. policy aims to accelerate competition among high-priced drugs, encouraging the entry of biosimilars and generic drugs, which could benefit Chinese pharmaceutical companies that can offer lower-cost alternatives [4][6] 5. **Opportunities for Chinese Pharmaceutical Companies** The reduction in U.S. drug prices is expected to create opportunities for Chinese companies, particularly in the fast-follow and biosimilar segments, as they can provide high-quality, cost-effective alternatives [6][8] 6. **Long-term Trends Favoring Chinese Innovation** The inefficiencies in innovation among multinational pharmaceutical companies may lead to increased reliance on Chinese innovation and manufacturing capabilities, especially if U.S. companies face cost pressures [7][8] 7. **Market Dynamics and Export Opportunities** The easing of trade tensions is anticipated to enhance the macroeconomic environment in China, leading to improved domestic demand and potential export opportunities for medical devices and raw materials [10][9] 8. **Impact of Drug Price Reductions on Market Dynamics** The anticipated drug price reductions in the U.S. are not expected to significantly diminish the addressable market for Chinese companies, as their market share in the U.S. remains relatively small [11][12] 9. **Long-term Supply Chain Considerations** U.S. concerns regarding supply chain security may lead to a push for domestic manufacturing, which could have long-term implications for Chinese companies seeking to penetrate the U.S. market [14][15] 10. **Investment Recommendations** The call suggests focusing on three categories of companies: innovative leaders, those with strong business development (BD) expectations, and upstream suppliers with global advantages, as the market enters a new growth cycle [16][18] Other Important but Possibly Overlooked Content 1. **Sector-Specific Insights** The discussion includes insights into specific companies and their competitive advantages, such as the potential for certain drugs to achieve significant market penetration despite pricing pressures [31][33] 2. **Emerging Trends in Medical Devices** The call also touches on the medical device sector, emphasizing the importance of high-end equipment and the potential for growth in home healthcare products, which may offer higher profit margins compared to domestic markets [25][26] 3. **Long-term Growth Projections** There is an optimistic outlook for the pharmaceutical sector, with expectations of a gradual recovery in demand and performance improvements in the coming years, driven by policy support and market dynamics [29][40] 4. **Focus on Innovation and R&D** The emphasis on innovation and the need for companies to adapt to changing market conditions is reiterated, highlighting the importance of R&D in maintaining competitive advantages [19][20] 5. **Market Sentiment and Future Outlook** The overall sentiment is cautiously optimistic, with a belief that the current market conditions present opportunities for growth and investment in the pharmaceutical and medical device sectors [46][47]